Montelukast PCD Pharma Franchise Company
Cafoli Lifecare offers a strong respiratory and allergy portfolio built around Montelukast, with 31 formulations across tablets, syrup and suspension, including combination products. All are manufactured at WHO-GMP certified facilities and offered on a monopoly basis.
What is Montelukast?
Montelukast is a selective leukotriene receptor antagonist. It blocks the CysLT1 receptor, preventing leukotriene-mediated bronchoconstriction, mucus secretion and airway inflammation, and is taken once daily as a controller (not a rescue) medicine. More information is available on MedlinePlus.
Therapeutic Applications
Montelukast is used for the prophylaxis and chronic control of bronchial asthma, exercise-induced bronchoconstriction and allergic rhinitis (both seasonal and perennial). Prescribers include pulmonologists, chest physicians, paediatricians, ENT specialists and general physicians.
Why Montelukast is a High-Potential Molecule for Distributors
Rising urban air pollution and allergy burden have made Montelukast one of the fastest-moving oral respiratory molecules in India. It is a maintenance therapy, so patients refill it for months, and the paediatric syrup and suspension formats open the large children's asthma and rhinitis market where inhaler compliance is poor. Combination packs with antihistamines further widen prescriber reach.
Why Choose Cafoli Lifecare
Cafoli offers district-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, attractive net rates and complete promotional inputs, with 1000+ franchise partners across India.
References
- MedlinePlus: Montelukast
- PubChem: Montelukast
Our formulations of Montelukast find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: